JP2008520703A - ２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用 - Google Patents

２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用 Download PDF

Info

Publication number
JP2008520703A
JP2008520703A JP2007543267A JP2007543267A JP2008520703A JP 2008520703 A JP2008520703 A JP 2008520703A JP 2007543267 A JP2007543267 A JP 2007543267A JP 2007543267 A JP2007543267 A JP 2007543267A JP 2008520703 A JP2008520703 A JP 2008520703A
Authority
JP
Japan
Prior art keywords
compound
administered
formula
hydroxy
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2007543267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520703A5 (enExample
Inventor
デルーカ，ヘクター・エフ
シシンスキ，ラファル・アール
プラム，ロリ・エイ
クラジェット−ダーム，マーガレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2008520703A publication Critical patent/JP2008520703A/ja
Publication of JP2008520703A5 publication Critical patent/JP2008520703A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
JP2007543267A 2004-11-22 2005-11-18 ２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用 Ceased JP2008520703A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63018404P 2004-11-22 2004-11-22
PCT/US2005/041817 WO2006057899A2 (en) 2004-11-22 2005-11-18 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses

Publications (2)

Publication Number Publication Date
JP2008520703A true JP2008520703A (ja) 2008-06-19
JP2008520703A5 JP2008520703A5 (enExample) 2009-01-15

Family

ID=36218156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543267A Ceased JP2008520703A (ja) 2004-11-22 2005-11-18 ２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用

Country Status (8)

Country Link
US (3) US7241751B2 (enExample)
EP (1) EP1846369A2 (enExample)
JP (1) JP2008520703A (enExample)
AU (1) AU2005309804B9 (enExample)
CA (1) CA2588399A1 (enExample)
MX (1) MX2007006542A (enExample)
NZ (1) NZ555283A (enExample)
WO (1) WO2006057899A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544502A1 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7244719B2 (en) * 2004-11-22 2007-07-17 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
AU2005309818A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1-alpha-hydroxy-bishomopregnacalciferol
NZ555283A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
ATE499942T1 (de) * 2004-11-22 2011-03-15 Wisconsin Alumni Res Found 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol
WO2006057884A2 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
US8193169B2 (en) * 2006-04-06 2012-06-05 Wisconsin Alumni Research Foundation (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
US8399439B2 (en) * 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
US7879829B2 (en) * 2008-07-10 2011-02-01 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2-dihydrofuran ring
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
US8193170B2 (en) * 2008-07-10 2012-06-05 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
US8217023B2 (en) 2009-10-02 2012-07-10 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
MX2012003883A (es) 2009-10-02 2012-06-27 Wisconsin Alumni Res Found Analogos de (20s,22e)-2-metileno-19-nor-22-ene-1a,25-dihidroxovita mina d3.
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
CN104086019A (zh) * 2014-06-17 2014-10-08 湖北富邦科技股份有限公司 一种工业高浓度含磷废水的处理方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
ES2309069T3 (es) * 2000-05-31 2008-12-16 Wisconsin Alumni Research Foundation Compuestos de 2-etil y 2-etiliden-19-nor-vitamina d.
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
EP1392323B1 (en) * 2001-05-22 2008-10-08 Bioxell S.p.a. Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
CA2544502A1 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
CA2588412A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2006057884A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
NZ555283A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses

Also Published As

Publication number Publication date
WO2006057899A2 (en) 2006-06-01
WO2006057899A3 (en) 2006-07-06
MX2007006542A (es) 2007-07-25
AU2005309804A1 (en) 2006-06-01
US20060160769A1 (en) 2006-07-20
AU2005309804B2 (en) 2011-09-29
US7241751B2 (en) 2007-07-10
US8093232B2 (en) 2012-01-10
AU2005309804B9 (en) 2011-12-08
US20070254857A1 (en) 2007-11-01
CA2588399A1 (en) 2006-06-01
US20120071562A1 (en) 2012-03-22
EP1846369A2 (en) 2007-10-24
NZ555283A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
US8093232B2 (en) 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses
US20060116352A1 (en) 2alpha-Methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
JP6383365B2 (ja) （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体
JP2011507966A (ja) ２−メチレン−２０−メチル−１９，２４，２５，２６，２７−ペンタノル−ビタミンｄ類縁体
US20080081800A1 (en) 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US8609643B2 (en) 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs
JP2008520691A (ja) ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
JP2008520705A (ja) ２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用
US8114859B2 (en) 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs
EP1817278B1 (en) 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses
US8399438B2 (en) 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
JP2011527700A (ja) ２−メチレン−２０（２１）−デヒドロ−１９−ノル−ビタミンｄ類似物質
JP2011527698A (ja) ２−メチレン−（２０ｅ）−２０（２２）−デヒドロ−１９−ノル−ビタミンｄ類似物質
US7947666B2 (en) 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs
JP2011527696A (ja) ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質
US8193169B2 (en) (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120307

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120619

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20121026